The severe acute respiratory syndrome caused by COVID-19 is now a global catastrophic event. Currently there is no approved drug or vaccine for the disease. Methylene blue (MB, oxidized form, blue color) has been used in many different areas of clinical medicine, ranging from malaria to orthopedics. Leucomethylene Blue (reduced form of MB, colorless) may be applied for the treatment of COVID-19 according to the scientific evidences.
Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)
A mixture of MCN will be injected to covid-19 patients.
Other Name: Leucomethylene Blue
Inclusion Criteria:
1. Confirmed case of Covid-19 (by RT-PCR, HRCT)
2. Admission to Intensive Care Unit
3. Need for intubation and mechanical ventilation (PaO2/FiO2 < 100-200)
4. Written informed consent
Exclusion Criteria:
1. Pregnancy and breastfeeding
2. History of G6PDH deficiency
3. Preadmission anticoagulation
4. Severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2)
5. Medical records of cirrhosis
6. Active chronic hepatitis
7. Severe hepatic disease defined by GOT or GPT levels three times above the normal upper
limit
8. Patients with history of allergic reaction or significant sensitivity to Methylene
blue
9. Treatment with immunosuppressive agents
10. Use of other investigational drugs in the moment of inclusion
Imam Reza Hospital
Mashhad, Razavi Khorasan, Iran, Islamic Republic of
Investigator: Ahmad Bagheri Moghaddam, M.D
Contact: 05138412081
bagheria@mums.ac.ir
Daryoush Hamidi Alamdari, Ph.D
+98 51 3882 8574
hamidiad@mums.ac.ir
Amir Yarahmadi, Ph.D
+98 51 3882 8574
yarahmadiA961@mums.ac.ir
Daryoush Hamidi Alamdari, Ph.D, Principal Investigator
Mashhad University of Medical Sciences, Mashhad, Iran